Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
April 07, 2023 18:50 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (the “FDA”)...
Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
March 30, 2023 18:10 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 30, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
March 09, 2023 10:02 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Participation in Upcoming Conferences
March 01, 2023 16:44 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
December 02, 2022 17:02 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
November 23, 2022 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
November 10, 2022 16:15 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 04, 2022 11:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces Participation in Four Upcoming Conferences
August 31, 2022 16:52 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results
August 11, 2022 16:10 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...